Citations

Clear

171 citation(s) found for "Moss, M".

Development of Entrustable Professional Activities for Advanced Inflammatory Bowel Disease Fellowship Training in the United States
Cohen, Benjamin L, Gallinger, Zane , Ha, Christina , Holubar, Stefan D. , Hou, Jason K. , Kinnucan, Jami , Mahadevan, Uma, Moss, Alan C. , Raffals, Laura E. , Szigethy, Eva , Wolf, Douglas C. , Dubinsky, Marla C. , Shah, Brijen J. , Ehrlich, Orna , Holubar, Stefan D , Cohen, Benjamin L, Regueiro, Miguel , Patel, Anish A , Hanauer, Stephen B.

Mayo Clinic

Inflammatory Bowel Diseases | August 21, 2020 | Volume: 26 | Issue: 9 | Pages: 1291-1305

10.1093/ibd/izaa177 | PMID 32820340 Get It

Abstract Background The level of inflammatory bowel disease (IBD) training in general gastroenterology fellowship is often insufficient to prepare trainees to deliver advanced IBD care in practice. Advanced IBD fellowships have been developed to fill this training gap, but there is no established curriculum, and significant variability exists across programs. Entrustable professional activities (EPAs) are practical and realistic objectives that define essential tasks of a specialty that physicians should master to be competent during independent practice. The American College of Gastroenterology (ACG) and Crohn’s & Colitis Foundation (Foundation) established a task force to develop and appraise EPAs for advanced IBD fellowship. Methods Entrustable professional activities were developed using a multistep approach in a similar manner to other specialties. Initial EPAs identified via focus groups were evaluated, critiqued, and changed using an iterative model of feedback. The final EPAs were selected after the task force conducted a 3-phase modified Delphi method consisting of 2 sequential rounds of web-based voting and an in-person consensus meeting. Results Ten EPAs for advanced IBD fellowship were established including detailed descriptions with the associated knowledge, skills, and attitudes for each that can serve as curricular milestones. Conclusion Ten EPAs describing the core work of an advanced IBD fellowship–trained physician have been established by a multisociety task force. Creating EPAs for an advanced curriculum comes with unique challenges, particularly the need to prevent duplication of prior training competencies while demonstrating the potential for unique milestones.
Impact of Clinical Pharmacists in Inflammatory Bowel Disease Centers During the COVID-19 Pandemic
Bhat, Shubha , Moss, Alan C. , Farraye, Francis A.

Mayo Clinic

American Journal of Gastroenterology | July 21, 2020 | Volume: 115 | Issue: 9 | Pages: 1532-1533

10.14309/ajg.0000000000000787 | PMID 32694291 Get It

INTRODUCTION: To characterize the clinical pharmacists' impact on caring for patients with inflammatory bowel disease during COVID-19. METHODS: A clinical pharmacist's encounters between March 17 and April 14, 2020, were audited to determine encounter frequency and indication. RESULTS: The clinical pharmacist addressed COVID-19 and inflammatory bowel disease treatment concerns with 140 patients, conducted 34 medication education and monitoring visits, reviewed 141 patients' charts and helped rescheduled 18 patients who missed their biologic infusion, transitioned 12 patients to home infusions, and assisted 5 patients with medication access. DISCUSSION: Clinical pharmacists embedded in gastroenterology practices permit for continued optimal patient care during a pandemic.
Tumor Emboli: A Rare Cause of Pulmonary Hypertension
Carter, L. , Burnside, Rebecca, Moss, James

Mayo Clinic

B54. PULMONARY HYPERTENSION ASSOCIATED WITH DRUGS; CANCER THERAPIES AND OTHER UNUSUAL DISEASES: CLINICAL STUDIES AND CASE REPORT | July 7, 2020 | Volume: No volume available | Issue: No issue available | Pages: A3762-A3762

10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a3762 Get It

Quality of Life of Patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH) and Idiopathic Pulmonary Arterial Hypertension (IPAH): The Pulmonary Hypertension Association Registry (PHAR)
Narasimmal, S.P., Pugliese, Steven C. , Bull, Todd M., Marco, Teresa De , McConnell, J.W. , Feldman, Jeremy P., Sager, Jeffrey S., Badesch, David B., Ryan, John , Grinnan, D. , Zwicke, Dianne, Elwing, Jean , Robinson, Jeffrey C. , Moss, James , Eggert, Michael, Shlobin, Oksana A. , Bartolome, Sonja, Mathai, S.C. , Mazimba, Sula , Lammi, Matthew R. , Thenappan, Thenappan , Horn, Evelyn M. , Frantz, Robert P. , Al‐Naamani, Nadine

Mayo Clinic

C104. LATEST CLINICAL INVESTIGATIONS IN ACUTE AND CHRONIC THROMBOEMBOLISM DISORDERS OF THE PULMONARY CIRCULATION | July 7, 2020 | Volume: No volume available | Issue: No issue available | Pages: A6048-A6048

10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a6048 Get It

Psychosocial and Financial Burden of Therapy in USA Patients with Pulmonary Arterial Hypertension
Helgeson, Scott A. , Menon, Divya Padmanabhan , Helmi, Haytham , Vadlamudi, Charitha , Moss, John E. , Zeiger, Tonya K., Burger, Charles D. , Helgeson, Scott A , Burger, Charles

Mayo Clinic

Diseases | June 15, 2020 | Volume: 8 | Issue: 2 | Pages: 22

10.3390/diseases8020022 | PMID 32545763 Get It

Pulmonary arterial hypertension (PAH) is a devastating disease with significant morbidity and mortality. There are many psychosocial and financial implications of this disease; however, little is known how this affects the treatment of PAH patients. A questionnaire-based prospective cohort study was performed on 106 PAH patients from a Pulmonary Hypertension Center and the Pulmonary Hypertension Association national conference in 2018. The demographic, treatment, psychosocial, employment, financial impact on treatment data was obtained. The majority of patients had cardiopulmonary symptoms despite treatment. The symptoms affected their social and work lives, with about one in three applying for disability because of their PAH. The majority of PAH patients had insurance coverage, but still noted a significant financial burden of the disease, with nearly a half who needed financial assistance to pay for their PAH medications. Thirty (28.3%; 95% CI, 20.6–37.5%) patients mentioned they changed their medication regimen, with some skipping doses outright (28 [26.4%; 95% CI, 19–35.6%]) in order to save money. PAH continues to cause significant psychosocial and financial burden on patients despite advances in medications. This impact ranged from dissatisfaction with quality of life, to unemployment, to altering their medication regimen to save money.
Outcomes and Health Care Utilization After Early Hospital Dismissal in Kidney Transplantation
Calderon, Esteban , Chang, James M. , Velazco, Cristine S. , Giorgakis, Emmanouil , Srinivasan, Ananth, Moss, Adyr A. , Khamash, Hasan , Heilman, Raymond L. , Reddy, Kunam S. , Mathur, Amit K. , Heilman, Raymond, Giorgakis, Emmanouil , Chang, Yu‐Hui , Srinivasan, Ananth

Mayo Clinic

Annals of Surgery | June 9, 2020 | Volume: 275 | Issue: 2 | Pages: e511-e519

10.1097/sla.0000000000003948 | PMID 32516231 Get It

Objective: To understand whether reduced lengths of stay after kidney transplantation were associated with excess health care utilization in the first 90 days or long-term graft and patient survival outcomes. Background: Reducing length of stay after kidney transplant has an unknown effect on post-transplant health care utilization. We studied this association in a cohort of 1001 consecutive kidney transplants. Methods: We retrospectively reviewed 2011–2015 data from a prospectively-maintained kidney transplant database from a single center. Results: A total of 1001 patients underwent kidney transplant, and were dismissed from the hospital in 3 groups: Early [≤2 days] (19.8%), Normal [3–7 days] (79.4%) and Late [>7 days] (3.8%). 34.8% of patients had living donor transplants (Early 51%, Normal 31.4%, Late 18.4%, P < 0.001). Early patients had lower delayed graft function rates (Early 19.2%, Normal 32%, Late73.7%, P = 0.001). By the hospital dismissal group, there were no differences in readmissions or emergency room visits at 30 or 90 days. Glomerular filtration rate at 12 months and rates of biopsy-proven acute rejection were also similar between groups. The timing of hospital dismissal was not associated with the risk-adjusted likelihood of readmission. Early and Normal patients had similar graft and patient survival. Late dismissal patients, who had higher rates of cardiovascular complications, had significantly higher late mortality versus Normal dismissal patients in unadjusted and risk-adjusted models. Conclusion: Dismissing patients from the hospital 2 days after kidney transplant is safe, feasible, and improves value. It is not associated with excess health care utilization or worse short or long-term transplant outcomes.
Acute Kidney Injury Patterns Following Transplantation of Steatotic Liver Allografts
Jadlowiec, Caroline C. , Neville, Matthew R., Abdelwahab, Dina, Reddy, Kunam S. , Moss, Adyr A. , Aqel, Bashar , Taner, Timuçin , Jadlowiec, Caroline , Neville, Matthew, Mao, Shennen, Aqel, Bashar A. , Taner, Timucin , Smith, Maxwell L. , Mao, Shennen A.

Mayo Clinic

Journal of Clinical Medicine | April 2, 2020 | Volume: 9 | Issue: 4 | Pages: 954

10.3390/jcm9040954 | PMID 32235545 Get It

Background: Steatotic grafts are increasingly being used for liver transplant (LT); however, the impact of graft steatosis on renal function has not been well described. Methods: A total of 511 allografts from Mayo Clinic Arizona and Minnesota were assessed. We evaluated post-LT acute kidney injury (AKI) patterns, perioperative variables and one-year outcomes for patients receiving moderately steatotic allografts (>30% macrovesicular steatosis, n = 40) and compared them to non-steatotic graft recipients. Results: Post-LT AKI occurred in 52.5% of steatotic graft recipients versus 16.7% in non-steatotic recipients (p < 0.001). Ten percent of steatotic graft recipients required new dialysis post-LT (p = 0.003). At five years, there were no differences for AKI vs. no AKI patient survival (HR 0.95, 95% CI 0.08–10.6, p = 0.95) or allograft survival (HR 1.73, 95% CI 0.23–13.23, p = 0.59) for those using steatotic grafts. Lipopeliosis on biopsy was common in those who developed AKI (61.0% vs. 31.6%, p = 0.04), particularly when the Model for End-Stage Liver Disease (MELD) was ≥20 (88.9%; p = 0.04). Lipopeliosis was a predictor of post-LT AKI (OR 6.0, 95% CI 1.1–34.6, p = 0.04). Conclusion: One-year outcomes for moderately steatotic grafts are satisfactory; however, a higher percentage of post-LT AKI and initiation of dialysis can be expected. Presence of lipopeliosis on biopsy appears to be predictive of post-LT AKI.
Is adjuvant oxaliplatin (Ox) overutilized in colon cancer (CC): 408 cases from the practices of 102 oncologists.
Ziel, Kathryn, Grothey, Axel, Hussein, Atif, Moss, Jonathan R., Love, Neil, Venook, Alan P. , Moss, Jonathan

Mayo Clinic

Journal of Clinical Oncology | March 11, 2020 | Volume: 31 | Issue: 15_suppl | Pages: e14564-e14564

10.1200/jco.2013.31.15_suppl.e14564 Get It

e14564 Background: Recent long-term clinical trial follow-up suggests that adding Ox to a fluoropyrimidine (FP) may provide less benefit in adjuvant CC than originally believed (Tournigand JCO 2012). In addition, emerging data on tissue biomarkers such as microsatellite mismatch repair (MMR) and the 12-gene Recurrence Score (RS) suggest these assays may be helpful in better defining treatment benefit, and a new report provides evidence that RS may specifically predict the value of Ox (O'Connell ASCO 2012). In view of these developments we sought to document current use of adjuvant chemotherapy and physician perceptions about these decisions. Methods: U.S.-based oncologists were recruited to complete a survey and contribute treatment data for their last three patients (pts) with stage II disease and last pt with a stage III tumor. Results: 25 gastrointestinal cancer clinical investigators and 77 practicing oncologists participated, providing data from a total of 408 cases (92% treated since 2011). Findings from the two groups are similar and are presented in aggregate. A median of 9 and 15 pts annually were evaluated with Stage II and III tumors, respectively. Clinicians stated that they require a median of a 5% absolute reduction in relapse rate to use a FP alone and an additional 5% reduction to add Ox. Ox/FP was administered to 95 of 102 pts with stage III tumors (93%) and 85 of 306 pts with stage II disease (28%), particularly to those under age 70 or with T4 tumors (Table). MMR was evaluated in 127 pts (42%) with stage II and 20 pts (20%) with stage III disease. RS was obtained for 46 pts (15%) with stage II tumors, but only 2 pts (2%) with stage III. Conclusions: Adjuvant Ox is employed widely in spite of the fact that it may provide less benefit than many oncologists report requiring to initiate its use. However, several recent research developments may be laying the groundwork for a change in this treatment practice. [Table: see text]
Heparin vs bivalirudin anticoagulation for extracorporeal membrane oxygenation
Kaseer, Haya , Soto‐Arenall, Matthew, Sanghavi, Devang , Moss, John, Ratzlaff, Robert A. , Pham, Si M. , Guru, Pramod , Ratzlaff, Robert, Pham, Si , Guru, Pramod K , Kaseer, Haya S , Moss, John E.

Mayo Clinic

Journal of Cardiac Surgery | February 12, 2020 | Volume: 35 | Issue: 4 | Pages: 779-786

10.1111/jocs.14458 | PMID 32048330 Get It